Skip to main content
. 2022 Feb 26;44(2):785–803. doi: 10.1007/s11357-022-00530-6

Fig. 1.

Fig. 1

Examination of PACAP-38 levels in healthy controls (control) (n = 37) and patients with Parkinson’s disease (PD). PD patients were divided into two groups, those who received deep brain stimulation (DBS) (n = 46) and those who were not treated with DBS (non-DBS) (n = 60). Significantly reduced PACAP-38 levels were measured in the non-DBS group compared to the control group. On the other hand, significantly elevated levels were detected in the DBS group compared to the non-DBS group. The boxes show the interquartile ranges, and the whiskers indicate the 25% and 75% percentile; outliers are also plotted with numbered data points labeled with circles and asterisk. The middle line within the boxes represents the median values. One-way ANOVA with Tukey’s post-hoc test, ** p < 0.001 vs. non-DBS group